Chong Kun Dang Pharmaceutical Corp.
Spun off and listed in 2013, Chong Kun Dang out-licensed its HDAC6 inhibitor CKD-510 to Novartis in a deal worth about KRW 1.7 trillion.
As of 2026-10-10, Chong Kun Dang Pharmaceutical Corp. has 2 Korean MFDS device approvals, 637 Korean MFDS drug approvals, 26 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureSpun off in November 2013 and listed on the KOSPI the following month, Chong Kun Dang Pharmaceutical is a pharmaceutical company. Its portfolio includes Camtobell, Korea's 8th approved new drug and an anticancer agent (2004); Duvie, Korea's 20th approved new drug for diabetes (2013); Nespevel, the world's first Nesp biosimilar approved in Korea and Japan; Jitec, a botanical drug for gastritis approved domestically in 2022; Lucentis biosimilar Lucenbiez, approved domestically in 2022 and launched in 2023; and existing products such as Gliatilin and Dilatrend. The company invests about 9-11% of revenue in R&D and, in November 2023, signed a technology out-licensing deal worth about KRW 1.7 trillion with Novartis for research, clinical development, and commercialization rights to the HDAC6 inhibitor CKD-510.
Products & technology
- CamtobellAnticancer agent (Korea's 8th approved new drug)
- DuvieDiabetes treatment (Korea's 20th approved new drug)
- NespevelNesp biosimilar
- JitecGastritis treatment (botanical drug)
- LucenbiezLucentis biosimilar
- Gliatilinexisting product
- Dilatrendexisting product
Regulatory approvals
data.go.kr637 Korean MFDS drug approvals · 1960–2026 / 2 Korean MFDS device approvals · 2018–2019
- MFDS drugCenzaluta Soft Cap. 40mg2026-09-15Drug · Prescription · Approval202602758
- MFDS drugJoint Chondro Max oral gel2026-09-02Drug · OTC · Notification202602609
- MFDS drugKefem Active Plaster2026-08-28Drug · OTC · Notification202602514
- MFDS drugZespan Max Tab.2026-08-25Drug · OTC · Notification202602461
- MFDS drugBelldoxia Tab. 15mg2026-08-21Drug · Prescription · Approval202602433
- MFDS drugBelldoxia Tab. 30mg2026-08-21Drug · Prescription · Approval202602434
- MFDS drugBelldoxia Tab. 60mg2026-08-21Drug · Prescription · Approval202602435
- MFDS drugVinobelin Injection2026-06-30Drug · Prescription · Approval202601860
- MFDS drugBenfobell Alpha Tab.2026-06-17Drug · OTC · Notification202601715
- MFDS drugPenzal 500 Powder2026-06-11Drug · OTC · Notification202601655
- MFDS drugModcol Cold Strong Soft Cap.2026-05-12Drug · OTC · Notification202601383
- MFDS drugModcol Nose Strong Soft Cap.2026-05-12Drug · OTC · Notification202601384
Show 68 more
- MFDS drugModcol Ibu Cough Soft Cap.2026-04-29Drug · OTC · Notification202601272
- MFDS drugModcol Tea Night Effervescent Tab.2026-04-29Drug · OTC · Notification202601276
- MFDS drugPenzal 500 Tab.2026-04-29Drug · OTC · Notification202601277
- MFDS drugModcol Ibu Cold Soft Cap.2026-04-24Drug · OTC · Notification202601208
- MFDS drugGenbig Triple Speed Solution2026-04-23Drug · OTC · Notification202601185
- MFDS drugModcol Cough Strong Soft Cap.2026-04-23Drug · OTC · Notification202601190
- MFDS drugModcol Ibu Nose Soft Cap.2026-04-15Drug · OTC · Notification202601089
- MFDS drugOlobella 0.7 SD Eye Drops2026-03-27Drug · Prescription · Approval202600865
- MFDS drugEsoduo-mini Tab. 10/350mg2026-03-27Drug · Prescription · Approval202600876
- MFDS drugGrabella 1.5% SD Ophthalmic solution2026-03-26Drug · Prescription · Approval202600847
- MFDS drugNeuropezil Tab. 3mg2026-03-18Drug · Prescription · Approval202600786
- MFDS drugDuviempol XR Tab. 0.25/12.5/1000mg2026-03-10Drug · Prescription · Approval202600714
- MFDS drugDuviempol XR Tab. 0.5/10/1000mg2026-03-10Drug · Prescription · Approval202600715
- MFDS drugDuviempol XR Tab. 0.5/25/1000mg2026-03-10Drug · Prescription · Approval202600716
- MFDS drugOtinib tablet 40 mg (Osimertinib mesylate)2026-01-27Drug · Prescription · Approval202600226
- MFDS drugOtinib tablet 80 mg (Osimertinib mesylate)2026-01-27Drug · Prescription · Approval202600227
- MFDS drugDuviempa Tab. 0.5/25mg2025-12-19Drug · Prescription · Approval202503330
- MFDS drugDuviempa Tab. 0.5/10mg2025-12-19Drug · Prescription · Approval202503331
- MFDS drugTelminuvo Plus Tab. 80/2.5/25mg2025-10-31Drug · Prescription · Approval202502824
- MFDS drugTelminuvo Plus Tab. 80/2.5/12.5mg2025-10-31Drug · Prescription · Approval202502825
- MFDS drugTelminuvo Plus Tab. 40/2.5/12.5mg2025-10-31Drug · Prescription · Approval202502826
- MFDS drugDermagram PDRN Cream2025-09-26Drug · OTC · Notification202502554
- MFDS drugBriveta Tablet 50mg (brivaracetam)2025-09-23Drug · Prescription · Approval202502511
- MFDS drugBriveta Tablet 10mg (brivaracetam)2025-09-23Drug · Prescription · Approval202502512
- MFDS drugBriveta Tablet 25mg (brivaracetam)2025-09-23Drug · Prescription · Approval202502513
- MFDS drugBriveta Tablet 100mg (brivaracetam)2025-09-23Drug · Prescription · Approval202502514
- MFDS drugTelminuvo Tab. 20/1.25mg(Telmisartan, S-Amlodipine Besylate Dihydrate)2025-08-29Drug · Prescription · Approval202502268
- MFDS drugKeyfobell powder2025-08-12Drug · OTC · Notification202502081
- MFDS drugBenfobell I Soft Cap.2025-08-11Drug · OTC · Notification202502077
- MFDS drugCenbido Injection2025-08-01Drug · Prescription · Approval202502017
- MFDS drugWonder-V inj.2025-07-31Drug · Prescription · Approval202502008
- MFDS drugCKD Topiramate XR tablet 25mg2025-07-25Drug · Prescription · Approval202501907
- MFDS drugCKD Topiramate XR tablet 50mg2025-07-25Drug · Prescription · Approval202501908
- MFDS drugEmpamax M XR tab. 10/1000mg2025-07-24Drug · Prescription · Approval202501898
- MFDS drugEmpamax M XR tab. 25/1000mg2025-07-24Drug · Prescription · Approval202501899
- MFDS drugEmpamax M XR tab. 12.5/750mg2025-07-24Drug · Prescription · Approval202501900
- MFDS drugEmpamax M XR tab. 12.5/1000mg2025-07-24Drug · Prescription · Approval202501901
- MFDS drugCKD Easyquick solution2025-07-18Drug · OTC · Notification202501826
- MFDS drugDermagram Soft Cap.2025-07-08Drug · OTC · Notification202501707
- MFDS drugZangTrahola Enteric Soft Capsule(Peppermint Oil)2025-06-25Drug · OTC · Approval202501572
- MFDS drugKefem Gongpas Plaster2025-06-17Drug · OTC · Notification202501474
- MFDS drugModcol Kidspen Syrup(Acetaminophen)2025-06-10Drug · OTC · Notification202501414
- MFDS drugKEFEM Cool & Hot Plaster2025-05-22Drug · OTC · Notification202501274
- MFDS drugPitalou F tab. 2/160mg2025-04-30Drug · Prescription · Approval202501048
- MFDS drugIriquick tablet 2.5mcg2025-04-30Drug · Prescription · Approval202501061
- MFDS drugIriquick tablet 5mcg2025-04-30Drug · Prescription · Approval202501066
- MFDS drugADCAL Q Tab.2025-04-28Drug · OTC · Notification202501017
- MFDS drugAdcal D Tab.2025-04-24Drug · OTC · Notification202500989
- MFDS drugNeuromanthyn Tab. 20mg2025-04-21Drug · Prescription · Approval202500939
- MFDS drugEmsiformin XR Tab. 12.5/50/750mg2025-04-16Drug · Prescription · Approval202500914
- MFDS drugEmsiformin XR Tab. 25/100/1000mg2025-04-16Drug · Prescription · Approval202500915
- MFDS drugEmsiformin XR Tab. 5/50/750mg2025-04-16Drug · Prescription · Approval202500916
- MFDS drugEmsiformin XR Tab. 10/100/1000mg2025-04-16Drug · Prescription · Approval202500917
- MFDS drugEmpamax S Tab. 25/100mg2025-04-07Drug · Prescription · Approval202500821
- MFDS drugEmpamax S Tab. 10/100mg2025-04-07Drug · Prescription · Approval202500822
- MFDS drugNUVOROZET tab. 80/2.5/10/10mg2025-03-21Drug · Prescription · Approval202500656
- MFDS drugNUVOROZET tab. 80/2.5/5/10mg2025-03-21Drug · Prescription · Approval202500657
- MFDS drugLipilouzet Tab. 10/5mg2024-12-27Drug · Prescription · Approval202403092
- MFDS drugNeuropezilM Tab. 10/20mg2024-12-23Drug · Prescription · Approval202403049
- MFDS drugGlowwings powderRevoked2024-10-21Drug · OTC · Notification202402467
- MFDS drugDermagram Gel2024-10-14Drug · OTC · Notification202402425
- MFDS drugEfinabell Topical Solution2024-07-08Drug · Prescription · Approval202401670
- MFDS drugTelminuvo Tab. 20/2.5mg(Telmisartan, S-Amlodipine Besylate Dihydrate)2024-07-04Drug · Prescription · Approval202401637
- MFDS drugCogniX Tab.2024-04-30Drug · OTC · Notification202401072
- MFDS drugNexcholine Tab. 10mg2024-04-24Drug · Prescription · Approval202400967
- MFDS drugOtebell Tab.2024-04-17Drug · Prescription · Approval202400869
- MFDS drugLipilou Tab. 5mg2024-03-11Drug · Prescription · Approval202400512
- MFDS drugNexcholine Tab. 30mg2024-02-26Drug · Prescription · Approval202400403
Showing the 80 most recent of 639 records.
Clinical trials
data.go.kr367 MFDS clinical trial authorisations · 2012–2026 (Phase 1 185 · Bioequivalence 134 · Phase 3 36 · Phase 2 10 · Phase 1/2a 2)
- Phase 3CKD-3392026-07-27
29 trial sites
- BioequivalenceCKD-2992026-07-24
2 trial sites
- BioequivalenceCKD-2292026-06-05
2 trial sites
- BioequivalenceCKD-2622026-04-30
1 trial site
- BioequivalenceCKD-2542026-03-10
1 trial site
- BioequivalenceCKD-2542026-03-10
1 trial site
- Phase 1/2aCKD-7032026-02-10
5 trial sites
- Phase 1CKD-3392026-01-30
2 trial sites
- BioequivalenceCKD-2992026-01-07
2 trial sites
- BioequivalenceCKD-2152025-11-26
5 trial sites
- Phase 1CKD-8462025-11-26
2 trial sites
- Phase 1CKD-3832025-09-23
2 trial sites
Show 68 more
- Phase 1CKD-3832025-09-23
2 trial sites
- Phase 1CKD-3832025-09-23
2 trial sites
- BioequivalenceCKD-2492025-07-29
2 trial sites
- Phase 3CKD-3562025-06-30
- BioequivalenceCKD-2162025-06-10
2 trial sites
- BioequivalenceCKD-2382025-03-27
2 trial sites
- BioequivalenceCKD-228(7_1)2025-03-21
1 trial site
- BioequivalenceCKD-228(4_1)2025-03-21
1 trial site
- BioequivalenceCKD-2682025-03-19
2 trial sites
- BioequivalenceCKD-2682025-03-19
2 trial sites
- BioequivalenceCKD-2182025-03-17
2 trial sites
- BioequivalenceCKD-228(14_1)2025-03-17
1 trial site
- Phase 1CKD-5122025-03-12
8 trial sites
- BioequivalenceCKD-2062024-12-04
2 trial sites
- Phase 1CKD-3242024-11-01
2 trial sites
- Phase 1CKD-3832024-10-31
2 trial sites
- Phase 1CKD-3832024-10-31
2 trial sites
- Phase 1CKD-3792024-10-21
2 trial sites
- Phase 1CKD-3782024-10-17
2 trial sites
- BioequivalenceD4892024-10-09
2 trial sites
- BioequivalenceCKD-2182024-08-09
2 trial sites
- Phase 3CKD-8432024-07-24
25 trial sites
- Phase 1CKD-3832024-06-12
2 trial sites
- Phase 1CKD-3782024-05-02
2 trial sites
- BioequivalenceCKD-2102024-04-08
2 trial sites
- Phase 1CKD-3832024-03-06
2 trial sites
- Phase 1CKD-3412024-02-05
2 trial sites
- BioequivalenceCKD-2062024-01-17
2 trial sites
- Phase 3CKD-202A2023-12-15
51 trial sites
- Phase 1CKD-3482023-11-29
2 trial sites
- Phase 1CKD-3792023-09-27
1 trial site
- Phase 1CKD-8462023-09-21
2 trial sites
- BioequivalenceD9782023-08-11
2 trial sites
- BioequivalenceD9782023-08-10
2 trial sites
- Phase 1CKD-3912023-08-07
2 trial sites
- BioequivalenceKBP-5012023-06-16
2 trial sites
- Phase 3CKD-8282023-05-22
11 trial sites
- Phase 1CKD-3412023-05-22
2 trial sites
- Phase 1CKD-3832023-05-18
2 trial sites
- Phase 1CKD-3792023-05-15
1 trial site
- BioequivalenceCKD-2092023-05-15
2 trial sites
- Phase 1CKD-8282023-05-08
- Phase 1CKD-3792023-04-26
1 trial site
- Phase 1CKD-3782023-04-24
2 trial sites
- Phase 1CKD-8282023-04-21
- BioequivalenceCKD-2062023-04-20
2 trial sites
- Phase 1CKD-3782023-03-24
2 trial sites
- Phase 1CKD-3832023-03-24
2 trial sites
- Phase 1CKD-3482023-02-22
2 trial sites
- Phase 1CKD-3862023-02-14
2 trial sites
- Phase 3CKD-8282023-02-07
17 trial sites
- Phase 1CKD-3792023-01-20
1 trial site
- Phase 1CKD-3872022-12-29
2 trial sites
- Phase 1CKD-3912022-12-15
2 trial sites
- Phase 3CKD-3912022-11-08
20 trial sites
- Phase 2CKD-4982022-10-17
16 trial sites
- Phase 1CKD-3412022-09-29
2 trial sites
- Phase 1CKD-8432022-09-20
2 trial sites
- Phase 1CKD-3862022-09-15
2 trial sites
- Phase 1CKD-3482022-09-15
2 trial sites
- Phase 1CKD-3712022-09-06
2 trial sites
- Phase 1CKD-8282022-08-26
- Phase 1CKD-3872022-07-26
2 trial sites
- Phase 1CKD-3872022-07-26
2 trial sites
- Phase 3CKD-8282022-07-26
9 trial sites
- Phase 3CKD-3712022-06-29
26 trial sites
- Phase 1CKD-3792022-05-31
1 trial site
- Phase 1CKD-3312022-04-18
2 trial sites
Showing the 80 most recent of 367 records.
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Not yet recruiting · 2026-08 · NCT07748702
Phase 1 · Not yet recruiting · 2026-06 · NCT07532148
Phase 1/2 · Recruiting · 2026-04 · NCT07439094
Phase 4 · Not yet recruiting · 2026-03 · NCT07365358
Phase 1 · Completed · 2026-02 · NCT07404735
Phase 1 · Recruiting · 2026-02 · NCT07358156
Phase 1 · Recruiting · 2025-11 · NCT07258745
Phase 1 · Completed · 2025-10 · NCT07304726
Phase 1 · Completed · 2025-10 · NCT07304700
Phase 1 · Completed · 2025-10 · NCT07304687
Show 289 more trials
Phase 1 · Recruiting · 2025-10 · NCT07215637
Phase 4 · Not yet recruiting · 2025-08 · NCT06942156
Phase 1 · Completed · 2025-05 · NCT06979973
Phase 2 · Completed · 2025-04 · NCT06954766
Phase 3 · Recruiting · 2025-04 · NCT06916793
Phase 1 · Completed · 2024-11 · NCT06758661
Phase 1 · Completed · 2024-11 · NCT06727396
Phase 1 · Completed · 2024-11 · NCT06709807
Phase 1 · Completed · 2024-11 · NCT06695572
Phase 1 · Completed · 2024-11 · NCT06695598
Phase 1 · Completed · 2024-11 · NCT06652971
Phase 3 · Recruiting · 2024-10 · NCT06643819
Phase 1 · Unknown · 2024-07 · NCT06492655
Phase 1 · Completed · 2024-05 · NCT06386328
Phase 1 · Completed · 2024-04 · NCT06483243
Phase 1 · Completed · 2024-03 · NCT06281132
Phase 1 · Completed · 2024-01 · NCT06112678
Recruiting · 2024-01 · NCT06838286
Phase 1 · Completed · 2023-11 · NCT06204107
Phase 4 · Completed · 2023-11 · NCT06044493
Phase 1 · Completed · 2023-11 · NCT06110923
Phase 1 · Completed · 2023-10 · NCT06088017
Phase 3 · Completed · 2023-07 · NCT06121518
Phase 1 · Completed · 2023-07 · NCT05698043
Phase 1 · Completed · 2023-07 · NCT05897216
Phase 1 · Completed · 2023-07 · NCT05928637
Phase 1 · Completed · 2023-07 · NCT05881707
Phase 3 · Completed · 2023-06 · NCT05931224
Phase 1 · Completed · 2023-06 · NCT05921435
Phase 1 · Unknown · 2023-06 · NCT05952219
Phase 1 · Completed · 2023-06 · NCT05881213
Phase 4 · Unknown · 2023-06 · NCT05843162
Phase 1 · Completed · 2023-05 · NCT05816759
Phase 1 · Completed · 2023-05 · NCT05834595
Phase 1 · Completed · 2023-04 · NCT05749861
Phase 4 · Unknown · 2023-04 · NCT06431477
Phase 1 · Completed · 2023-04 · NCT05741437
Phase 1 · Completed · 2023-02 · NCT05719155
Phase 1 · Completed · 2023-02 · NCT05673369
Phase 1 · Completed · 2022-12 · NCT05634447
Phase 2 · Completed · 2022-12 · NCT05677438
Phase 4 · Unknown · 2022-11 · NCT06430047
Phase 3 · Unknown · 2022-11 · NCT05657574
Phase 1 · Completed · 2022-11 · NCT05587699
Phase 1 · Completed · 2022-11 · NCT05571813
Phase 1 · Completed · 2022-10 · NCT05544214
Phase 3 · Completed · 2022-10 · NCT05566028
Phase 1 · Completed · 2022-09 · NCT05549401
Phase 3 · Unknown · 2022-09 · NCT05526703
Phase 1 · Completed · 2022-09 · NCT05552495
Phase 1 · Completed · 2022-09 · NCT06399068
Phase 1 · Completed · 2022-09 · NCT06399055
Phase 1 · Completed · 2022-09 · NCT05540912
Phase 1 · Completed · 2022-08 · NCT05526742
Phase 1 · Completed · 2022-07 · NCT05452525
Phase 1 · Completed · 2022-06 · NCT05274880
Phase 1 · Completed · 2022-05 · NCT05335044
Phase 1 · Completed · 2022-04 · NCT05347576
Phase 1 · Completed · 2022-03 · NCT05245084
Phase 1 · Completed · 2022-02 · NCT05238948
Phase 1 · Completed · 2022-02 · NCT05192356
Phase 1 · Completed · 2022-01 · NCT05207761
Phase 1 · Completed · 2022-01 · NCT05189288
Phase 1 · Completed · 2021-11 · NCT05113693
Phase 4 · Active not recruiting · 2021-11 · NCT05193565
Phase 1 · Completed · 2021-11 · NCT05089279
Phase 1 · Unknown · 2021-10 · NCT05108038
Phase 4 · Unknown · 2021-09 · NCT05041790
Phase 1 · Completed · 2021-09 · NCT04987970
Phase 4 · Unknown · 2021-09 · NCT05050604
- Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers
Phase 1 · Completed · 2021-07 · NCT04952506
Phase 3 · Unknown · 2021-06 · NCT04871646
Phase 1 · Unknown · 2021-06 · NCT04906785
Phase 1 · Completed · 2021-06 · NCT04883658
Phase 1 · Unknown · 2021-06 · NCT04906798
Phase 1 · Completed · 2021-05 · NCT04869800
Phase 1 · Completed · 2021-04 · NCT04805606
Phase 1 · Unknown · 2021-04 · NCT04867200
Phase 1 · Completed · 2021-04 · NCT04830930
Phase 1 · Completed · 2021-04 · NCT04810676
Phase 1 · Unknown · 2021-04 · NCT04840745
Phase 1 · Completed · 2021-03 · NCT04768673
Phase 4 · Unknown · 2021-03 · NCT04867720
Phase 1 · Unknown · 2021-02 · NCT04676893
Phase 1 · Completed · 2021-02 · NCT04694989
Phase 1 · Unknown · 2021-02 · NCT04706286
Phase 1 · Completed · 2021-01 · NCT04673864
Phase 1 · Completed · 2021-01 · NCT04660370
Phase 4 · Unknown · 2021-01 · NCT04700709
Phase 2 · Completed · 2020-12 · NCT04628143
Phase 1 · Completed · 2020-11 · NCT04673682
Phase 1 · Unknown · 2020-11 · NCT04673695
Phase 1 · Unknown · 2020-11 · NCT04611932
Phase 1 · Unknown · 2020-11 · NCT04627207
Phase 1 · Unknown · 2020-10 · NCT04678388
Phase 1 · Unknown · 2020-10 · NCT04651881
Phase 1 · Completed · 2020-10 · NCT04587206
Phase 1 · Unknown · 2020-09 · NCT04703374
Phase 2 · Completed · 2020-09 · NCT04623021
Phase 3 · Completed · 2020-09 · NCT04548427
Phase 1 · Unknown · 2020-07 · NCT04478097
Phase 1 · Completed · 2020-07 · NCT04488900
Phase 4 · Completed · 2020-06 · NCT04471441
Phase 1 · Completed · 2020-06 · NCT04431687
Phase 2 · Unknown · 2020-06 · NCT04448223
Phase 1 · Unknown · 2020-05 · NCT04667975
Phase 1 · Completed · 2020-05 · NCT04334213
Phase 1 · Completed · 2020-04 · NCT04260438
Phase 1 · Unknown · 2020-04 · NCT04322032
Phase 1 · Completed · 2020-03 · NCT04258865
Phase 1 · Unknown · 2020-02 · NCT04246190
Phase 1 · Completed · 2020-02 · NCT04304547
Phase 1 · Unknown · 2020-02 · NCT04223895
Phase 1 · Unknown · 2020-01 · NCT04221360
Phase 1 · Completed · 2020-01 · NCT04746287
Phase 3 · Completed · 2020-01 · NCT04255589
Phase 1 · Completed · 2019-10 · NCT04354987
Phase 3 · Unknown · 2019-10 · NCT04388215
Phase 1 · Completed · 2019-09 · NCT04075643
Phase 1 · Completed · 2019-09 · NCT04083846
Phase 1 · Completed · 2019-09 · NCT04083872
Phase 3 · Completed · 2019-08 · NCT04312698
Phase 1 · Completed · 2019-08 · NCT04156685
Phase 1 · Unknown · 2019-08 · NCT04035538
Phase 4 · Unknown · 2019-07 · NCT04069065
Phase 1 · Completed · 2019-07 · NCT04019743
Phase 1 · Completed · 2019-06 · NCT04272502
- A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation
Phase 3 · Unknown · 2019-04 · NCT03950843
Phase 1 · Unknown · 2019-04 · NCT03848637
Phase 1 · Unknown · 2019-04 · NCT03920579
Phase 1 · Completed · 2019-03 · NCT03887858
Phase 1 · Completed · 2019-03 · NCT03887871
Phase 1 · Completed · 2019-02 · NCT03858725
Phase 1 · Unknown · 2019-02 · NCT03849287
- Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers
Phase 1 · Completed · 2019-02 · NCT03868072
Phase 1 · Unknown · 2019-02 · NCT03849495
Phase 1 · Completed · 2019-02 · NCT03802162
Phase 4 · Completed · 2019-01 · NCT03928470
Phase 1 · Unknown · 2019-01 · NCT03849339
Phase 1 · Unknown · 2019-01 · NCT03849261
Phase 1 · Completed · 2019-01 · NCT03738449
- Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus
Completed · 2019-01 · NCT05043467
Phase 4 · Unknown · 2018-12 · NCT04224350
Phase 3 · Unknown · 2018-12 · NCT03762369
Phase 2 · Completed · 2018-11 · NCT04204603
Phase 1 · Unknown · 2018-10 · NCT03748212
Phase 3 · Completed · 2018-10 · NCT04857177
Phase 4 · Completed · 2018-09 · NCT04539652
Phase 1 · Completed · 2018-09 · NCT03793985
Phase 4 · Completed · 2018-09 · NCT03749356
Phase 1 · Unknown · 2018-08 · NCT03726866
Phase 1 · Unknown · 2018-08 · NCT03646799
Phase 1 · Completed · 2018-08 · NCT03609606
Phase 1 · Completed · 2018-08 · NCT03659149
Phase 1 · Completed · 2018-07 · NCT03616392
Phase 1 · Unknown · 2018-07 · NCT03601910
Phase 1 · Completed · 2018-06 · NCT03558425
Phase 2 · Completed · 2018-05 · NCT03726853
Phase 1 · Completed · 2018-05 · NCT03671941
Phase 1 · Unknown · 2018-05 · NCT03713892
Phase 3 · Unknown · 2018-05 · NCT03641352
- Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes
Phase 3 · Unknown · 2018-04 · NCT03627182
Phase 1 · Completed · 2018-04 · NCT03569579
Phase 3 · Completed · 2018-04 · NCT03583905
Phase 4 · Completed · 2018-03 · NCT03794492
Phase 1 · Completed · 2018-03 · NCT03444402
Phase 2 · Completed · 2018-01 · NCT03437785
Completed · 2018-01 · NCT06974903
Phase 4 · Completed · 2017-11 · NCT04102943
- Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes
Phase 3 · Completed · 2017-11 · NCT03739125
Phase 1 · Completed · 2017-10 · NCT03382756
Phase 4 · Completed · 2017-10 · NCT04511000
Phase 4 · Completed · 2017-09 · NCT04521023
Phase 1 · Completed · 2017-06 · NCT03211143
Phase 1 · Completed · 2017-05 · NCT03346187
Phase 1 · Unknown · 2017-05 · NCT03150316
Phase 1 · Completed · 2017-05 · NCT03175835
Phase 2 · Unknown · 2017-03 · NCT03067415
Phase 2 · Completed · 2017-03 · NCT02977065
Phase 1 · Completed · 2017-03 · NCT03210649
Phase 1 · Completed · 2017-02 · NCT03034486
Phase 1 · Unknown · 2017-01 · NCT03051841
Phase 4 · Completed · 2016-12 · NCT03067194
Phase 1 · Completed · 2016-12 · NCT03017950
Phase 1/2 · Unknown · 2016-12 · NCT03076957
Phase 1 · Completed · 2016-08 · NCT02916901
Phase 1 · Completed · 2016-08 · NCT02894541
Phase 1 · Unknown · 2016-08 · NCT02854748
Phase 3 · Unknown · 2016-05 · NCT02777723
Phase 1 · Completed · 2016-04 · NCT02824874
Phase 1 · Completed · 2016-04 · NCT02753504
Phase 1 · Completed · 2016-04 · NCT03233932
Phase 1 · Completed · 2016-04 · NCT02827890
Phase 3 · Unknown · 2016-04 · NCT02805738
Phase 1 · Completed · 2016-02 · NCT02685774
Phase 3 · Completed · 2016-01 · NCT02586311
Phase 1 · Completed · 2016-01 · NCT02651753
Phase 1 · Completed · 2015-12 · NCT02615782
Unknown · 2015-11 · NCT03063697
Phase 1 · Completed · 2015-11 · NCT02645890
Phase 4 · Unknown · 2015-10 · NCT02588937
Phase 1 · Completed · 2015-10 · NCT02648854
Phase 1 · Completed · 2015-10 · NCT02623868
Phase 1 · Completed · 2015-10 · NCT02589457
Phase 1 · Completed · 2015-09 · NCT02631954
Phase 3 · Completed · 2015-09 · NCT03246880
Phase 1 · Completed · 2015-08 · NCT02501200
Phase 1 · Completed · 2015-08 · NCT02548286
Phase 1 · Completed · 2015-08 · NCT02627027
Phase 1 · Completed · 2015-07 · NCT02565368
Phase 1 · Completed · 2015-07 · NCT02461004
Phase 3 · Completed · 2015-06 · NCT03428594
Phase 1 · Completed · 2015-06 · NCT02484482
Phase 3 · Completed · 2015-05 · NCT03431623
Phase 3 · Completed · 2015-05 · NCT02498509
Phase 3 · Completed · 2015-04 · NCT02651870
Phase 1 · Completed · 2015-04 · NCT02811731
Phase 1 · Completed · 2015-04 · NCT02801526
Phase 4 · Unknown · 2015-04 · NCT02526875
Phase 1 · Completed · 2015-03 · NCT02422030
Phase 3 · Completed · 2015-03 · NCT02451098
Phase 1 · Completed · 2015-02 · NCT02358824
Phase 1 · Completed · 2015-01 · NCT02336854
Phase 4 · Unknown · 2015-01 · NCT02480465
Phase 1 · Completed · 2014-11 · NCT02288338
Phase 1 · Completed · 2014-09 · NCT02247505
Phase 1 · Completed · 2014-09 · NCT02247518
Phase 1 · Completed · 2014-09 · NCT02250833
Phase 4 · Completed · 2014-08 · NCT02356679
Phase 1 · Completed · 2014-07 · NCT02186496
Phase 4 · Completed · 2014-06 · NCT02231788
Phase 1 · Completed · 2014-06 · NCT02064621
Phase 1 · Completed · 2014-06 · NCT02156544
Phase 1 · Completed · 2014-05 · NCT02064556
Phase 1 · Completed · 2014-04 · NCT02007941
Phase 1 · Completed · 2014-03 · NCT02066207
Phase 2 · Unknown · 2014-03 · NCT02206165
Phase 1 · Completed · 2014-03 · NCT02005744
Phase 1 · Completed · 2014-02 · NCT02047175
Phase 3 · Unknown · 2014-01 · NCT01983735
Phase 1 · Completed · 2013-12 · NCT02002611
Phase 3 · Unknown · 2013-12 · NCT01956201
Phase 2 · Unknown · 2013-11 · NCT02005757
Completed · 2013-08 · NCT01910077
Phase 1 · Completed · 2013-04 · NCT01842230
Phase 1 · Unknown · 2013-04 · NCT01819870
Phase 1 · Completed · 2013-04 · NCT01842256
Phase 4 · Completed · 2013-04 · NCT01860482
Phase 4 · Completed · 2013-01 · NCT01842269
Phase 4 · Completed · 2013-01 · NCT01756937
Phase 4 · Completed · 2012-12 · NCT01743287
Phase 3 · Completed · 2012-12 · NCT01756430
Phase 1 · Completed · 2012-10 · NCT01685671
Phase 1 · Completed · 2012-10 · NCT01684605
Phase 4 · Completed · 2012-08 · NCT01746680
Phase 3 · Completed · 2012-07 · NCT01634295
Phase 4 · Terminated · 2012-06 · NCT01766505
Phase 1 · Completed · 2012-06 · NCT01560325
Phase 1 · Completed · 2012-05 · NCT01580371
Phase 4 · Completed · 2012-01 · NCT01682564
Phase 3 · Completed · 2011-08 · NCT01426100
Phase 1 · Completed · 2011-08 · NCT01496261
Phase 3 · Completed · 2011-08 · NCT01501253
Phase 1 · Completed · 2011-07 · NCT01340248
Phase 1 · Completed · 2011-06 · NCT01356017
Phase 1 · Completed · 2011-06 · NCT01369472
Phase 1 · Completed · 2011-05 · NCT01356043
Phase 1 · Completed · 2011-04 · NCT01352689
Phase 1 · Completed · 2011-04 · NCT01341392
Phase 1 · Completed · 2011-03 · NCT01330563
Phase 2 · Completed · 2011-01 · NCT01630018
Phase 1 · Completed · 2011-01 · NCT01340131
Phase 1 · Completed · 2010-12 · NCT01663038
Phase 1 · Completed · 2010-11 · NCT01270984
Phase 1 · Completed · 2010-11 · NCT01246193
Phase 2 · Completed · 2010-09 · NCT01497873
Phase 2 · Completed · 2010-07 · NCT01128322
Phase 1 · Completed · 2010-05 · NCT01133431
Phase 3 · Completed · 2010-05 · NCT01106131
Phase 1 · Completed · 2010-03 · NCT01071720
Phase 1 · Completed · 2009-12 · NCT01028859
Phase 4 · Unknown · 2009-11 · NCT01766518
Phase 3 · Completed · 2009-10 · NCT01001611
Phase 1 · Completed · 2009-10 · NCT01005160
Phase 2 · Completed · 2009-09 · NCT01022671
Phase 1 · Completed · 2009-08 · NCT01019941
Phase 1 · Completed · 2009-07 · NCT01016626
Phase 4 · Completed · 2008-08 · NCT01029522
Phase 2 · Completed · 2007-07 · NCT01030679
R&D and key agreements
Source: DART corporate disclosureCKD-510 · HDAC6 저해제 · Signed a technology out-licensing agreement with Novartis in November 2023 for research, clinical development, and commercialization rights, valued at about KRW 1.7 trillion.
표적항암제·바이오신약 파이프라인 · 임상 진행중 · Conducting clinical trials for various new drug candidates including targeted anticancer agents and biologics.
Key disclosures
KRX KIND via OpenDARTShow 8 more events
Publications
PubMed · affiliation-matched- LMT328, a sulfiredoxin inhibitor, induces preferential cancer cell death and tumor regression via oxidative stress.
Free radical biology & medicine · 2026-08 · Lee GR, Kwon M, Kim T 외 6
- Pharmacokinetics, toxicities, and tissue concentrations of belotecan sprayed by rotational intraperitoneal pressurized aerosol chemotherapy in a pig model.
Journal of gynecologic oncology · 2025-05 · Lee S, Lee S, Song YK 외 5
- ROsulord® sAfety for Patients with Dyslipidemia Study: A Non-interventional, Multicenter, Prospective, Observational Study in South Korea.
Cardiology and therapy · 2025-03 · Kim DY, Kim SH, Kim EJ 외 6
- HDAC6 mediates NLRP3 inflammasome activation in the pathogenesis of diabetic retinopathy.
Metabolism: clinical and experimental · 2025-03 · Kim JS, Jun JH, Lee J 외 16
- A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis.
Canadian journal of gastroenterology & hepatology · 2025-01 · Park SH, Lee OY, Lee YC 외 15
- Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants.
Advances in therapy · 2024-07 · Kim JH, Song JH, Kim M 외 3
- A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects.
Pharmaceuticals (Basel, Switzerland) · 2024-04 · Jiang X, Yu KS, Nam DH 외 1
- Dysregulation of histone deacetylases in ocular diseases.
Archives of pharmacal research · 2024-01 · Jun JH, Kim JS, Palomera LF 외 1
- Efficacy and safety of CKD-495 in acute and chronic gastritis: A Phase III superiority clinical trial.
Medicine · 2023-12 · Seo SY, Lee ST, Kim SK 외 16
- A Randomized Trial of Nafamostat for Covid-19.
NEJM evidence · 2023-11 · Morpeth SC, Venkatesh B, Totterdell JA 외 61
Show 16 more publications
- A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of huntington's disease.
BMB reports · 2023-03 · Li E, Choi J, Sim HR 외 11
- CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer.
Toxicological research · 2023-01 · Kim SJ, Lee K, Park J 외 5
- Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects.
Drug design, development and therapy · 2023-01 · Jiang X, Bae S, Yoon DY 외 4
- A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus.
Diabetes & metabolism journal · 2022-11 · Kim BY, Kwon HS, Kim SK 외 16
- CKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy.
Biomolecules & therapeutics · 2022-09 · Kim SJ, Kim S, Choi YJ 외 2
- Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone.
Clinical pharmacology in drug development · 2022-05 · Park J, Kim CO, Oh ES 외 9
- Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects.
Translational and clinical pharmacology · 2021-09 · Moon SJ, Kim Y, Jeon JY 외 3
- Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.
International journal of molecular sciences · 2020-06 · Kim SJ, Kim UJ, Yoo HY 외 2
- Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer.
Cancer chemotherapy and pharmacology · 2020-04 · Kim SJ, Jegal KH, Im JH 외 5
- Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects.
Clinical pharmacology in drug development · 2019-07 · Kim SY, Jeon JY, Park SJ 외 1
- The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male.
Drug design, development and therapy · 2019-01 · Kim D, Park MS, Yoo BW 외 3
- Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
Scientific reports · 2018-01 · Jang JY, Bae H, Lee YJ 외 6
- New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients.
Drug design, development and therapy · 2017-01 · Kim YK, Kim A, Park SJ 외 1
- Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects.
Drug design, development and therapy · 2016-01 · Kim CO, Oh ES, Choi C 외 4
- Modulation of Adjuvant Arthritis by Cellular and Humoral Immunity to Hsp65.
Frontiers in immunology · 2016-01 · Kim EY, Durai M, Mia Y 외 2
- Effects of protein transduction domain combination for intracellular recombinant protein delivery.
Journal of controlled release : official journal of the Controlled Release Society · 2015-09 · Lee JH, Park EJ, Woo YS 외 2
Patents
KIPRIS · applicant-matchedPublished · 2026-07 · Application 1020260125594
Published · 2026-02 · Application 1020260028011
Published · 2025-12 · Application 1020250209340
Published · 2025-12 · Application 1020250202570
Published · 2025-12 · Application 1020250202164
PCT · Published · 2025-10 · Application PCT/KR2025/017027
PCT · Published · 2025-09 · Application PCT/KR2025/014593
Published · 2025-07 · Application 1020250105456
PCT · Published · 2025-07 · Application PCT/IB2025/057781
PCT · Published · 2025-06 · Application PCT/KR2025/008854
Show 351 more patents
Published · 2025-06 · Application 1020250081605
TW · Published · 2025-06 · Application 114123145
PCT · Published · 2025-06 · Application PCT/KR2025/008533
Published · 2025-06 · Application 1020250080643
Published · 2025-06 · Application 1020250077148
Published · 2025-05 · Application 1020250067035
PCT · Published · 2025-04 · Application PCT/KR2025/005450
PCT · Published · 2025-04 · Application PCT/KR2025/005076
Published · 2025-03 · Application 1020250034267
TW · Published · 2025-02 · Application 114106085
PCT · Published · 2025-02 · Application PCT/IB2025/051745
PCT · Published · 2025-02 · Application PCT/KR2025/002169
TW · Published · 2025-02 · Application 114104750
Published · 2025-02 · Application 1020250014731
Published · 2024-12 · Application 1020240183957
Published · 2024-12 · Application 1020240181160
PCT · Published · 2024-12 · Application PCT/KR2024/020014
Published · 2024-11 · Application 1020240167015
Published · 2024-11 · Application 1020240161022
Published · 2024-10 · Application 1020240147674
Published · 2024-09 · Application 1020240127289
CN · Published · 2024-06 · Application 202480043839.5
TW · Published · 2024-06 · Application 113124268
Published · 2024-06 · Application 1020240085170
PCT · Published · 2024-06 · Application PCT/IB2024/056306
Published · 2024-06 · Application 1020240084024
CN · Published · 2024-05 · Application 202480035656.9
PCT · Published · 2024-05 · Application PCT/KR2024/095864
Published · 2024-04 · Application 1020240054415
Published · 2024-04 · Application 1020240050770
CN · Published · 2024-02 · Application 202480015446.3
TW · Published · 2024-02 · Application 113107103
Registered · 2024-02 · Application 1020240028139
PCT · Published · 2024-02 · Application PCT/IB2024/051845
Withdrawn · 2024-02 · Application 1020240024627
Published · 2024-02 · Application 1020240021362
PCT · Published · 2024-01 · Application PCT/KR2024/001378
Registered · 2024-01 · Application 1020240003010
PCT · Published · 2024-01 · Application PCT/KR2024/000159
TW · Registered · 2024-01 · Application 113100169
PCT · Published · 2024-01 · Application PCT/KR2024/000076
Published · 2023-12 · Application 1020230193470
CN · Published · 2023-12 · Application 202380089267.X
TW · Published · 2023-12 · Application 112150708
Published · 2023-12 · Application 1020230190796
PCT · Published · 2023-12 · Application PCT/IB2023/063232
Rejected · 2023-11 · Application 1020230149399
TW · Registered · 2023-10 · Application 112140202
CN · Published · 2023-10 · Application 202380065122.6
Rejected · 2023-10 · Application 1020230140624
PCT · Published · 2023-10 · Application PCT/KR2023/016295
CN · Published · 2023-10 · Application 202380072424.6
TW · Published · 2023-10 · Application 112139001
Published · 2023-10 · Application 1020230136308
US · Published · 2023-10 · Application 19118934
PCT · Published · 2023-10 · Application PCT/IB2023/060289
PCT · Published · 2023-09 · Application PCT/KR2023/014414
PCT · Published · 2023-09 · Application PCT/KR2023/014295
CN · Published · 2023-09 · Application 202380063034.2
TW · Registered · 2023-09 · Application 112134022
PCT · Published · 2023-09 · Application PCT/KR2023/013453
CN · Published · 2023-07 · Application 202380050083.2
TW · Registered · 2023-07 · Application 112126127
Published · 2023-07 · Application 1020257004986
US · Published · 2023-07 · Application 18881499
PCT · Published · 2023-07 · Application PCT/IB2023/057181
Published · 2023-05 · Application 1020230070427
CN · Published · 2023-05 · Application 202380040758.5
TW · Published · 2023-05 · Application 112117865
Published · 2023-05 · Application 1020230062707
PCT · Published · 2023-05 · Application PCT/IB2023/054969
Registered · 2023-05 · Application 1020230057100
CN · Published · 2023-04 · Application 202380032254.9
TW · Published · 2023-04 · Application 112112921
PCT · Published · 2023-04 · Application PCT/KR2023/004684
Registered · 2023-02 · Application 1020230015791
Registered · 2023-01 · Application 1020230013161
CN · Published · 2023-01 · Application 202380018750.9
CN · Published · 2023-01 · Application 202380018757.0
Published · 2023-01 · Application 1020230010441
Published · 2023-01 · Application 1020230010442
US · Published · 2023-01 · Application 18833728
PCT · Published · 2023-01 · Application PCT/IB2023/050659
PCT · Published · 2023-01 · Application PCT/IB2023/050658
TW · Published · 2023-01 · Application 112102879
TW · Published · 2023-01 · Application 112102875
Published · 2023-01 · Application 1020230001726
Rejected · 2023-01 · Application 1020230001432
Registered · 2023-01 · Application 1020230000653
Registered · 2022-12 · Application 1020220181702
Withdrawn · 2022-12 · Application 1020220168779
Rejected · 2022-12 · Application 1020220166482
TW · Published · 2022-10 · Application 111140937
Withdrawn · 2022-10 · Application 1020220140567
PCT · Published · 2022-10 · Application PCT/IB2022/060326
Rejected · 2022-09 · Application 1020220121209
Rejected · 2022-09 · Application 1020220119359
Registered · 2022-09 · Application 1020220114318
Registered · 2022-09 · Application 1020220112210
TW · Published · 2022-08 · Application 111132770
Published · 2022-08 · Application 1020220109420
US · Published · 2022-08 · Application 18686193
PCT · Published · 2022-08 · Application PCT/IB2022/058096
Registered · 2022-07 · Application 1020220091692
CN · Published · 2022-04 · Application 202280022844.9
TW · Registered · 2022-04 · Application 111115277
US · Published · 2022-04 · Application 18287743
Registered · 2022-04 · Application 1020220049770
CN · Published · 2022-04 · Application 202280027084.0
TW · Registered · 2022-04 · Application 111113165
Registered · 2022-04 · Application 1020220043429
Withdrawn · 2022-03 · Application 1020220036778
Withdrawn · 2022-02 · Application 1020220016094
Registered · 2022-01 · Application 1020220002441
CN · Published · 2021-12 · Application 202180086128.2
PCT · Published · 2021-12 · Application PCT/KR2021/019777
Rejected · 2021-12 · Application 1020210181043
CN · Published · 2021-12 · Application 202180077817.7
TW · Registered · 2021-12 · Application 110145722
PCT · Published · 2021-12 · Application PCT/KR2021/018414
Registered · 2021-10 · Application 1020210147023
CN · Published · 2021-10 · Application 202180088618.6
EP · Published · 2021-10 · Application 21886807.3
CN · Published · 2021-09 · Application 202180053894.9
TW · Published · 2021-09 · Application 110132427
US · Registered · 2021-09 · Application 18024081
Rejected · 2021-08 · Application 1020210110342
Withdrawn · 2021-07 · Application 1020210099451
Rejected · 2021-07 · Application 1020210095728
CN · Published · 2021-07 · Application 202180061215.2
TW · Published · 2021-07 · Application 110125754
Registered · 2021-07 · Application 1020210091902
PCT · Published · 2021-07 · Application PCT/IB2021/056282
CN · Published · 2021-06 · Application 202180046461.0
Registered · 2021-06 · Application 1020210084599
US · Published · 2021-06 · Application 18010399
EP · Published · 2021-06 · Application 21833046.2
Withdrawn · 2021-06 · Application 1020210083913
Withdrawn · 2021-06 · Application 1020210083116
CN · Published · 2021-06 · Application 202180055754.5
Registered · 2021-06 · Application 1020210082309
EP · Published · 2021-06 · Application 21856055.5
TW · Published · 2021-05 · Application 110118583
CN · Published · 2021-04 · Application 202180027885.2
TW · Registered · 2021-04 · Application 110113120
US · Published · 2021-04 · Application 17995947
Registered · 2021-04 · Application 1020210046134
CN · Published · 2021-02 · Application 202180017040.5
CN · Published · 2021-02 · Application 202180016680.4
TW · Published · 2021-02 · Application 110106776
US · Registered · 2021-02 · Application 17904806
US · Registered · 2021-02 · Application 17904809
EP · Registered · 2021-02 · Application 21760387.7
EP · Registered · 2021-02 · Application 21760609.4
CN · Published · 2021-02 · Application 202180015913.9
US · Published · 2021-02 · Application 17801057
Registered · 2021-01 · Application 1020210006848
Registered · 2020-12 · Application 1020200183655
Registered · 2020-12 · Application 1020200183904
Rejected · 2020-12 · Application 1020200183419
CN · Published · 2020-12 · Application 202080088291.8
Rejected · 2020-12 · Application 1020200170136
Published · 2020-11 · Application 1020200144721
Rejected · 2020-10 · Application 1020200137579
Registered · 2020-10 · Application 1020200130563
Registered · 2020-09 · Application 1020200114971
Rejected · 2020-09 · Application 1020200114910
Registered · 2020-09 · Application 1020200111966
Registered · 2020-08 · Application 1020200102535
Registered · 2020-07 · Application 1020200086634
US · Published · 2020-07 · Application 17630261
Rejected · 2020-06 · Application 1020200069248
Registered · 2020-05 · Application 1020200065507
Registered · 2020-05 · Application 1020200065508
US · Published · 2020-05 · Application 17614967
EP · Registered · 2020-05 · Application 20814548.2
Registered · 2020-05 · Application 1020200055484
Registered · 2020-04 · Application 1020200052150
Registered · 2020-04 · Application 1020200044730
Rejected · 2020-03 · Application 1020200029788
Registered · 2020-02 · Application 1020200025195
Withdrawn · 2020-02 · Application 1020200025410
Registered · 2020-02 · Application 1020200023251
Registered · 2020-02 · Application 1020200023249
Registered · 2020-02 · Application 1020200021913
Rejected · 2020-02 · Application 1020200014802
Registered · 2019-12 · Application 1020190169482
CN · Published · 2019-12 · Application 201980084810.0
Registered · 2019-12 · Application 1020190168844
Registered · 2019-12 · Application 1020190166531
EP · Registered · 2019-12 · Application 19895962.9
Rejected · 2019-12 · Application 1020190162994
Rejected · 2019-11 · Application 1020190151726
Registered · 2019-10 · Application 1020217014773
CN · Published · 2019-10 · Application 201980067009.5
Rejected · 2019-10 · Application 1020190126443
Expired · 2019-09 · Application 1020190117235
Registered · 2019-09 · Application 1020190111646
Registered · 2019-07 · Application 1020190091283
EP · Registered · 2019-07 · Application 19841767.7
Registered · 2019-05 · Application 1020190061475
US · Published · 2019-05 · Application 17049737
Expired · 2019-04 · Application 1020190040122
US · Published · 2019-02 · Application 16970292
CN · Published · 2019-01 · Application 201980007209.1
Withdrawn · 2018-11 · Application 1020180134730
Registered · 2018-07 · Application 1020180087455
Expired · 2018-07 · Application 1020180086406
US · Registered · 2018-07 · Application 16633326
Registered · 2018-07 · Application 1020180084950
Registered · 2018-06 · Application 1020180071811
Registered · 2018-06 · Application 1020180065107
Registered · 2018-05 · Application 1020180061888
US · Registered · 2018-05 · Application 16616345
Registered · 2018-05 · Application 1020180058753
Expired · 2018-05 · Application 1020180057131
Registered · 2018-04 · Application 1020180049840
Rejected · 2018-04 · Application 1020180041378
Withdrawn · 2018-04 · Application 1020180041662
Registered · 2018-03 · Application 1020180029191
Rejected · 2018-02 · Application 1020180020058
Registered · 2018-01 · Application 1020180010980
Registered · 2018-01 · Application 1020180010987
Registered · 2018-01 · Application 1020180004301
Registered · 2018-01 · Application 1020180004458
Expired · 2017-11 · Application 1020170158867
Registered · 2017-11 · Application 1020170152226
Withdrawn · 2017-11 · Application 1020170146731
CN · Published · 2017-11 · Application 201780083157.7
US · Published · 2017-11 · Application 16466353
EP · Published · 2017-11 · Application 17891094.9
US · Published · 2017-10 · Application 15793501
CN · Published · 2017-09 · Application 201780061019.9
Expired · 2017-09 · Application 1020217011934
Rejected · 2017-09 · Application 1020197008761
EP · Registered · 2017-09 · Application 17853334.5
Expired · 2017-07 · Application 1020170094780
Registered · 2017-07 · Application 1020170089572
Registered · 2017-07 · Application 1020170089533
Registered · 2017-06 · Application 1020170078424
Registered · 2017-05 · Application 1020170062484
Registered · 2017-03 · Application 1020170033944
US · Registered · 2017-03 · Application 15447247
Withdrawn · 2017-02 · Application 1020170018647
Registered · 2017-01 · Application 1020170004418
EP · Published · 2016-12 · Application 16876001.5
Expired · 2016-12 · Application 1020160163318
JP · Published · 2016-11 · Application 30545099
Registered · 2016-10 · Application 1020160131245
EP · Registered · 2016-10 · Application 16855690.0
Withdrawn · 2016-10 · Application 1020160129644
Expired · 2016-10 · Application 1020160127767
Registered · 2016-09 · Application 1020160126879
PCT · Published · 2016-08 · Application PCT/KR2016/009393
Registered · 2016-08 · Application 1020160099508
EP · Registered · 2016-08 · Application 16833369.8
Expired · 2016-07 · Application 1020160096672
Registered · 2016-07 · Application 1020160095332
Registered · 2016-07 · Application 1020160095334
US · Registered · 2016-07 · Application 15747952
US · Registered · 2016-07 · Application 15748081
US · Registered · 2016-07 · Application 15747850
Registered · 2016-07 · Application 1020160095326
EP · Registered · 2016-07 · Application 16830837.7
EP · Registered · 2016-07 · Application 16830836.9
EP · Registered · 2016-07 · Application 16830838.5
Withdrawn · 2016-05 · Application 1020160062829
Expired · 2016-05 · Application 1020160062381
US · Registered · 2016-05 · Application 15575672
EP · Registered · 2016-05 · Application 16800269.9
Registered · 2015-12 · Application 1020150178339
PCT · Published · 2015-11 · Application PCT/KR2015/011801
Registered · 2015-10 · Application 1020150150108
Withdrawn · 2015-09 · Application 1020150135262
Registered · 2015-09 · Application 1020150130317
Abandoned · 2015-06 · Application 1020150091408
Rejected · 2015-06 · Application 1020150083997
Expired · 2015-03 · Application 1020150034556
EP · Registered · 2015-03 · Application 15762410.7
Expired · 2015-02 · Application 1020150028542
Abandoned · 2015-02 · Application 1020150017923
Expired · 2015-01 · Application 1020150013586
US · Published · 2015-01 · Application 15108873
Rejected · 2014-12 · Application 1020140190123
Registered · 2014-12 · Application 1020140190653
CN · Published · 2014-12 · Application 201480073461.X
US · Registered · 2014-12 · Application 15103597
Expired · 2014-12 · Application 1020140179702
EP · Registered · 2014-12 · Application 14869323.7
Abandoned · 2014-12 · Application 1020140175720
Expired · 2014-11 · Application 1020140164986
EP · Registered · 2014-11 · Application 14866648.0
Registered · 2014-11 · Application 1020140153759
US · Published · 2014-09 · Application 14502101
Expired · 2014-07 · Application 1020140091774
Expired · 2014-07 · Application 1020140091947
Expired · 2014-07 · Application 1020140091951
Withdrawn · 2014-07 · Application 1020140089233
Registered · 2014-04 · Application 1020140051151
EP · Registered · 2014-04 · Application 14792173.8
Withdrawn · 2014-04 · Application 1020140038467
Registered · 2014-04 · Application 1020140038468
Rejected · 2014-03 · Application 1020140035353
Withdrawn · 2014-02 · Application 1020140019807
Registered · 2014-01 · Application 1020140011555
EP · Registered · 2014-01 · Application 14746389.7
Expired · 2014-01 · Application 1020140000802
US · Published · 2013-12 · Application 14440058
US · Registered · 2013-12 · Application 14440060
EP · Registered · 2013-12 · Application 13867921.2
Withdrawn · 2013-12 · Application 1020130163884
Registered · 2013-12 · Application 1020130158961
Expired · 2013-08 · Application 1020130103747
EP · Registered · 2013-08 · Application 13833207.7
Expired · 2013-08 · Application 1020130100912
Expired · 2013-06 · Application 2020130005310
Expired · 2013-06 · Application 1020130066224
EP · Registered · 2013-06 · Application 13804551.3
Expired · 2013-05 · Application 2020130004226
EP · Registered · 2013-04 · Application 13788202.3
Rejected · 2013-04 · Application 1020130046543
Rejected · 2013-04 · Application 1020130046259
Registered · 2013-02 · Application 1020130022333
Expired · 2013-02 · Application 1020130013808
Expired · 2012-12 · Application 1020120157582
Expired · 2012-12 · Application 1020120157562
Registered · 2012-12 · Application 1020120157583
US · Registered · 2012-11 · Application 14357375
EP · Registered · 2012-11 · Application 12847217.2
Rejected · 2012-10 · Application 1020120119668
US · Published · 2012-10 · Application 14354206
Registered · 2012-08 · Application 1020120095874
EP · Registered · 2012-08 · Application 12826818.2
Registered · 2012-08 · Application 1020120093677
Rejected · 2012-06 · Application 2020120004972
Expired · 2012-05 · Application 1020120057883
Expired · 2012-05 · Application 1020120048805
Expired · 2012-04 · Application 1020120038143
Expired · 2012-04 · Application 1020120037886
Registered · 2011-11 · Application 1020110117082
Registered · 2011-10 · Application 1020110106230
Expired · 2011-06 · Application 1020110056685
Withdrawn · 2010-07 · Application 1020100072026
EP · Registered · 2010-03 · Application 10756300.9
EP · Registered · 2009-03 · Application 09725663.0
Expired · 2008-02 · Application 1020080016881
Rejected · 2008-02 · Application 1020080016515
PCT · Published · 2005-03 · Application PCT/KR2005/000666
US · Published · 2003-12 · Application 10538686
EP · Registered · 2002-03 · Application 02713320.6
EP · Registered · 1998-10 · Application 98947987.8
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive3
- OpenAIOAI-SearchBot73
- PerplexityPerplexityBot3
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Chong Kun Dang Pharmaceutical Corp. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSPI-listed pharmaceutical company behind the combination drugs Amosartan (hypertension) and Rosuzet (dyslipidemia).
KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.
L&C BIO manufactures human tissue grafts across 11 tissue types, including the acellular dermal matrix MegaDerm, plus tissue-based medical devices.
KOSDAQ-listed pharmaceutical and healthcare company producing lidocaine anesthetics and the Kynix hyaluronic-acid eye-drop line.
KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.
KOSDAQ-listed pharmaceutical company producing a diverse, low-volume portfolio of metabolic disease drugs, wellness injections, and veterinary medicines.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
Contract research organization providing clinical trial, post-marketing surveillance, and site management services to pharma and medtech clients.
KOSDAQ-listed holding company making medical devices and biologics including bone graft rhBMP2 and knee implant TKR.
CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition